Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Mar;16(3):60.
doi: 10.3892/mco.2022.2493. Epub 2022 Jan 12.

Cervical dissecting extravasation of oxaliplatin: A case report

Affiliations
Case Reports

Cervical dissecting extravasation of oxaliplatin: A case report

Jorge Hernando et al. Mol Clin Oncol. 2022 Mar.

Abstract

Oxaliplatin is a chemotherapy drug considered to be an irritant and vesicant. Peripheral extravasation could happen following oxaliplatin chemotherapy administration, but mediastinal or cervical events are rare. The present study focused on the case of a 64-year-old female patient with KRAS-mutated colorectal adenocarcinoma. The patient was prescribed folinic acid, fluorouracil and oxaliplatin chemotherapy via a subcutaneous pump or port-a-cath device, which was inserted into the right subclavian vein. The patient reported a sudden throbbing pain in the chest wall and anterior cervical region. After performing a computed tomography scan, anterior cervical collection and jugular-subclavian venous confluence at the distal end was observed at the venous access site of the subcutaneous port-a-cath device, which extended cranially, dissected cervical planes and forming a hydro-aerial collection in the submaxillary region. Subsequently, the port-a-cath device was removed and a warm dry compress was applied. After 2 weeks, the patient had fully recovered without any sequelae at the cervical level. To the best of the authors' knowledge, this is the first case of cervical extravasation of oxaliplatin reported in the literature to date and will help to manage similar situations.

Keywords: extravasation; oxaliplatin.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Upper thoracic and cervical swelling (arrowed) during oxaliplatin infusion.
Figure 2
Figure 2
Computed tomography scan images of extravasation. (A) Air bubbles (arrowed) extended cranially, dissecting laterocervical planes. (B) Subcutaneous inflammation (arrowed) was observed in the upper thoracic wall.
Figure 3
Figure 3
Computed tomography scan images on day 10 following admission. Imaging findings indicated resolution of the cervical hydro-aerial collection (arrowed).

References

    1. Yuan X, Zhang W, He Y, Yuan J, Song D, Chen H, Qin W, Qian X, Yu H, Guo Z. Proteomic analysis of cisplatin- and oxaliplatin-induced phosphorylation in proteins bound to Pt-DNA adducts. Metallomics. 2020;12:1834–1840. doi: 10.1039/d0mt00194e. - DOI - PubMed
    1. Spanish Agency for Medicines and Health Products (AEMPS): Technical datasheet of oxaliplatin. AEMPS, Madrid, 2021. https://cima.aemps.es/cima/publico.html. Accessed January 22, 2021.
    1. Goodsell DS. The molecular perspective: Cisplatin. Oncologist. 2006;11:316–317. doi: 10.1634/stemcells.2006-CSC2. - DOI - PubMed
    1. Bahadori F, Demiray M. Management of extravasation of oxaliplatin by mimicking its biotransformation. Clin Transl Oncol. 2018;20:1353–1357. doi: 10.1007/s12094-018-1854-z. - DOI - PubMed
    1. Baur M, Kienzer HR, Rath T, Dittrich C. Extravasation of oxaliplatin (Eloxatin((R)))-clinical course. Onkologi. 2000;23:468–471. doi: 10.1159/000027218. - DOI - PubMed

Publication types